We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+15.65%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$23.7B
AUM Growth
+$6.7B
(+39%)
Cap. Flow
+$3.87B
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
42.3%
Holding
1,113
New
41
Increased
800
Reduced
228
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.89B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$702M |
| 3 |
Qualcomm
QCOM
|
+$111M |
| 4 |
Apple
AAPL
|
+$86.9M |
| 5 |
Microsoft
MSFT
|
+$85.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$64.2M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$55.5M |
| 3 |
Intel
INTC
|
+$44M |
| 4 |
Advanced Micro Devices
AMD
|
+$29.1M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$17.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.04% |
| 2 | Financials | 10.33% |
| 3 | Healthcare | 6.19% |
| 4 | Consumer Discretionary | 4.07% |
| 5 | Energy | 2.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Alnylam Pharmaceuticals
ALNY
$27.5B
| $10.1M | 0.04% |
52,808
+8,640
| +20% | +$1.47M |
|
277
Neurocrine Biosciences
NBIX
$16.8B
| $10.1M | 0.04% |
76,549
-4,941
| -6% | -$569K |
|
278
Intellia Therapeutics
NTLA
$1.49B
| $10M | 0.04% |
328,998
+77,873
| +31% | +$2.24M |
|
279
Madrigal Pharmaceuticals
MDGL
$10.8B
| $9.97M | 0.04% |
43,099
-2,224
| -5% | -$389K |
|
280
Insmed
INSM
$21.4B
| $9.95M | 0.04% |
321,087
+47,563
| +17% | +$1.23M |
|
281
Vaxcyte
PCVX
$7.81B
| $9.95M | 0.04% |
158,413
-5,481
| -3% | -$285K |
|
282
Sarepta Therapeutics
SRPT
$1.57B
| $9.95M | 0.04% |
103,153
+28,973
| +39% | +$2.78M |
|
283
Bank OZK
OZK
$5.6B
| $9.86M | 0.04% |
197,850
-4,681
| -2% | -$193K |
|
284
Arch Capital
ACGL
$34.3B
| $9.82M | 0.04% |
132,274
+7,122
| +6% | +$582K |
|
|
CADE
285
DELISTED
Cadence Bank
CADE
| $9.82M | 0.04% |
331,932
+132,672
| +67% | +$3.24M |
|
286
Exelixis
EXEL
$13.3B
| $9.79M | 0.04% |
408,079
+5,421
| +1% | +$118K |
|
287
TG Therapeutics
TGTX
$7.96B
| $9.75M | 0.04% |
571,126
-285,711
| -33% | -$3.32M |
|
288
Pinnacle Financial Partners Inc
PNFP
$15.9B
| $9.68M | 0.04% |
111,012
+35,134
| +46% | +$2.55M |
|
289
TJX Companies
TJX
$174B
| $9.67M | 0.04% |
103,104
+4,217
| +4% | +$378K |
|
290
Natera
NTRA
$38.3B
| $9.67M | 0.04% |
154,404
-9,873
| -6% | -$493K |
|
291
Zoetis
ZTS
$32.4B
| $9.66M | 0.04% |
48,958
-1,051
| -2% | -$186K |
|
292
Immunovant
IMVT
$7.93B
| $9.65M | 0.04% |
229,087
-67,745
| -23% | -$2.49M |
|
293
Alkermes
ALKS
$8.22B
| $9.63M | 0.04% |
347,177
+38,632
| +13% | +$1M |
|
294
Fair Isaac
FICO
$24.3B
| $9.49M | 0.04% |
8,155
+1,176
| +17% | +$1.18M |
|
295
Associated Banc-Corp
ASB
$5.83B
| $9.42M | 0.04% |
440,620
+210,433
| +91% | +$3.79M |
|
296
PTC Therapeutics
PTCT
$5.68B
| $9.37M | 0.04% |
339,963
+133,676
| +65% | +$3.06M |
|
|
NUVL
297
DELISTED
Nuvalent
NUVL
| $9.35M | 0.04% |
127,046
+31,331
| +33% | +$1.94M |
|
|
MRTX
298
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.34M | 0.04% |
158,931
-90,681
| -36% | -$5.1M |
|
299
Ionis Pharmaceuticals
IONS
$8.6B
| $9.33M | 0.04% |
184,396
-31,575
| -15% | -$1.51M |
|
300
BioMarin Pharmaceuticals
BMRN
$11.6B
| $9.31M | 0.04% |
96,599
-2,126
| -2% | -$188K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Rafferty Asset Management held 1,113 positions worth $23.7B, up 39% from $17B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Rafferty Asset Management deployed $3.87B of net new capital in Q4 2023, opening 41 new positions and adding to 800 existing holdings. Its largest new stake was Splunk Inc: 70,916 shares worth $10.8M.
By sector, the portfolio is most concentrated in Technology at 40% of assets, down from 43% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Texas Instruments, an estimated $64.2M trimmed.
- Rafferty Asset Management's largest Q4 2023 buy was Splunk Inc: 70,916 shares worth $10.8M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2023, an estimated $1.89B increase.
- Rafferty Asset Management's biggest Q4 2023 reduction was Texas Instruments, cutting an estimated $64.2M.
- Rafferty Asset Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $17.8M.
- Rafferty Asset Management's ten largest holdings make up 42% of its $23.7B portfolio in Q4 2023.
- Rafferty Asset Management opened 41 new positions and closed 43 in Q4 2023.
- Rafferty Asset Management's portfolio value rose 39% quarter-over-quarter to $23.7B.
Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.